Iberdomide is an oral cereblon-modulating protein degrader (CELMoD) used with daratumumab and hyaluronidase-fihj and dexamethasone to treat previously treated multiple myeloma, acting by degrading the transcription factors Ikaros and Aiolos. It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros, producing both anti-tumor and immunomodulatory activity.
- Mechanism
- Curator reviewed
Pharmacologically active on Protein cereblon, DNA-binding protein Ikaros, and Zinc finger protein Aiolos
- Primary indication
- Iberdomide is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and...Curator reviewed · 1 structured indication
- Formula / weight
- C25H27N3O5 · 449.507 g/mol (avg)
- Code names
- BMS-986382 · CC-220
Resolves to
IXZOHGPZAQLIBH-NRFANRHFSA-NSMILESO=C1N(CC2=C1C=CC=C2OCC1=CC=C(CN2CCOCC2)C=C1)[C@H]1CCC(=O)NC1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Iberdomide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account